Cell Guidance Systems Limited 07122793 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is research and development in biotechnology. Digita Accounts Production Advanced 6.30.9574.0 true 07122793 2024-01-01 2024-12-31 07122793 2024-12-31 07122793 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-12-31 07122793 bus:OrdinaryShareClass2 bus:Non-cumulativeShares 2024-12-31 07122793 core:CurrentFinancialInstruments 2024-12-31 07122793 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 07122793 core:Non-currentFinancialInstruments core:AfterOneYear 2024-12-31 07122793 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-12-31 07122793 core:FurnitureFittings 2024-12-31 07122793 core:LandBuildings core:ShortLeaseholdAssets 2024-12-31 07122793 core:MotorVehicles 2024-12-31 07122793 core:OfficeEquipment 2024-12-31 07122793 core:PlantMachinery 2024-12-31 07122793 bus:SmallEntities 2024-01-01 2024-12-31 07122793 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 07122793 bus:FilletedAccounts 2024-01-01 2024-12-31 07122793 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 07122793 bus:RegisteredOffice 2024-01-01 2024-12-31 07122793 bus:Director2 2024-01-01 2024-12-31 07122793 bus:Director3 2024-01-01 2024-12-31 07122793 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-01-01 2024-12-31 07122793 bus:OrdinaryShareClass2 bus:Non-cumulativeShares 2024-01-01 2024-12-31 07122793 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 07122793 bus:Agent1 2024-01-01 2024-12-31 07122793 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-01-01 2024-12-31 07122793 core:IntangibleAssetsOtherThanGoodwill 2024-01-01 2024-12-31 07122793 core:ComputerEquipment 2024-01-01 2024-12-31 07122793 core:FurnitureFittings 2024-01-01 2024-12-31 07122793 core:LandBuildings core:ShortLeaseholdAssets 2024-01-01 2024-12-31 07122793 core:MotorVehicles 2024-01-01 2024-12-31 07122793 core:OfficeEquipment 2024-01-01 2024-12-31 07122793 core:PlantMachinery 2024-01-01 2024-12-31 07122793 countries:EnglandWales 2024-01-01 2024-12-31 07122793 2023-12-31 07122793 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-12-31 07122793 core:FurnitureFittings 2023-12-31 07122793 core:LandBuildings core:ShortLeaseholdAssets 2023-12-31 07122793 core:MotorVehicles 2023-12-31 07122793 core:OfficeEquipment 2023-12-31 07122793 core:PlantMachinery 2023-12-31 07122793 2023-01-01 2023-12-31 07122793 2023-12-31 07122793 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2023-12-31 07122793 bus:OrdinaryShareClass2 bus:Non-cumulativeShares 2023-12-31 07122793 core:CurrentFinancialInstruments 2023-12-31 07122793 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 07122793 core:Non-currentFinancialInstruments core:AfterOneYear 2023-12-31 07122793 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-12-31 07122793 core:FurnitureFittings 2023-12-31 07122793 core:LandBuildings core:ShortLeaseholdAssets 2023-12-31 07122793 core:MotorVehicles 2023-12-31 07122793 core:OfficeEquipment 2023-12-31 07122793 core:PlantMachinery 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07122793

Cell Guidance Systems Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2024

 

Cell Guidance Systems Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

Cell Guidance Systems Limited

Company Information

Directors

Dr Michael Howard Jones

Dr Jonathan Mark Treherne

Registered office

Maia Building
Babraham Research Campus
Cambridge
Cambridgeshire
CB22 3AT

Accountants

Tayabali & White 5 High Green
Great Shelford
Cambridge
CB22 5EG

 

Cell Guidance Systems Limited

(Registration number: 07122793)
Balance Sheet as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Intangible assets

4

3,162,316

2,840,921

Tangible assets

5

91,399

98,272

 

3,253,715

2,939,193

Current assets

 

Stocks

6

28,997

30,302

Debtors

7

178,919

158,036

Cash at bank and in hand

 

183,620

136,096

 

391,536

324,434

Creditors: Amounts falling due within one year

8

(271,857)

(274,139)

Net current assets

 

119,679

50,295

Total assets less current liabilities

 

3,373,394

2,989,488

Creditors: Amounts falling due after more than one year

8

(180,137)

(321,416)

Net assets

 

3,193,257

2,668,072

Capital and reserves

 

Called up share capital

9

64,798

62,177

Share premium reserve

2,490,257

2,076,917

Retained earnings

638,202

528,978

Shareholders' funds

 

3,193,257

2,668,072

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

 

Cell Guidance Systems Limited

(Registration number: 07122793)
Balance Sheet as at 31 December 2024

Approved and authorised by the Board on 11 April 2025 and signed on its behalf by:
 

.........................................
Dr Michael Howard Jones
Director

.........................................
Dr Jonathan Mark Treherne
Director

 

Cell Guidance Systems Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The company's registered number is 07122793.

The address of its registered office is:
Maia Building
Babraham Research Campus
Cambridge
Cambridgeshire
CB22 3AT

These financial statements were authorised for issue by the Board on 11 April 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date.

 

Cell Guidance Systems Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Laboratory equipment

25% on reducing balance

Furniture and fixtures

20% on reducing balance

Office equipment

20% on reducing balance

Computer equipment

20% on reducing balance

Intangible assets

Intangible assets include capitalised research and development costs that are stated at cost less any identified impairment provision. Intangible assets are amortised over an estimated life of twenty years using the straight-line method. If there is an indication that there has been a significant reduction in the useful life or residual value of an intangible asset, the amortisation rate is revised accordingly.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Development costs

Straight line over 20 years

 

Cell Guidance Systems Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 16 (2023 - 17).

4

Intangible assets

Research and development costs
 £

Total
£

Cost or valuation

At 1 January 2024

3,623,997

3,623,997

Additions acquired separately

529,048

529,048

At 31 December 2024

4,153,045

4,153,045

Amortisation

At 1 January 2024

783,076

783,076

Amortisation charge

207,653

207,653

At 31 December 2024

990,729

990,729

Carrying amount

At 31 December 2024

3,162,316

3,162,316

At 31 December 2023

2,840,921

2,840,921

 

Cell Guidance Systems Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

5

Tangible assets

Short leasehold land and buildings
£

Fixtures and fittings
£

Plant and machinery
£

Office equipment
£

Motor vehicles
 £

Cost or valuation

At 1 January 2024

-

4,096

295,565

16,691

1,821

Additions

4,687

2,633

8,857

2,111

1,029

Disposals

-

-

-

(432)

(272)

At 31 December 2024

4,687

6,729

304,422

18,370

2,578

Depreciation

At 1 January 2024

-

3,648

203,252

11,599

1,402

Charge for the year

234

497

24,025

1,106

178

Eliminated on disposal

-

-

-

(305)

(249)

At 31 December 2024

234

4,145

227,277

12,400

1,331

Carrying amount

At 31 December 2024

4,453

2,584

77,145

5,970

1,247

At 31 December 2023

-

448

92,313

5,092

419

 

Cell Guidance Systems Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Total
£

Cost or valuation

At 1 January 2024

318,173

Additions

19,317

Disposals

(704)

At 31 December 2024

336,786

Depreciation

At 1 January 2024

219,901

Charge for the year

26,040

Eliminated on disposal

(554)

At 31 December 2024

245,387

Carrying amount

At 31 December 2024

91,399

At 31 December 2023

98,272

Included within the net book value of land and buildings above is £4,453 (2023 - £Nil) in respect of short leasehold land and buildings.
 

6

Stocks

2024
£

2023
£

Raw materials and consumables

28,997

30,302

7

Debtors

Current

2024
£

2023
£

Trade debtors

137,183

123,967

Prepayments

35,206

22,562

Other debtors

6,530

11,507

 

178,919

158,036

 

Cell Guidance Systems Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

8

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Loans and borrowings

178,838

163,045

Trade creditors

 

31,513

88,784

Taxation and social security

 

10,060

13,267

Other creditors

 

51,446

9,043

 

271,857

274,139

Creditors: amounts falling due after more than one year

Note

2024
£

2023
£

Due after one year

 

Loans and borrowings

180,137

321,416

9

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary A shares of £0.01 each

5,936,271

59,363

5,936,271

59,363

Ordinary B shares of £0.01 each

281,384

2,814

281,384

2,814

6,217,655

62,177

6,217,655

62,177